{"drugs":["Elaprase","Idursulfase"],"mono":{"0":{"id":"928570-s-0","title":"Generic Names","mono":"Idursulfase"},"1":{"id":"928570-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928570-s-1-4","title":"Adult Dosing","mono":"<b>Mucopolysaccharidosis, MPS-II:<\/b> 0.5 mg\/kg IV once a week, administered by infusion initially over 3 hours; may decrease infusion to 1 hour if no hypersensitivity reactions observed; infusion may last up to 8 hours if required to manage hypersensitivity reaction "},"1":{"id":"928570-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in pediatric patients younger than 16 months; no data available demonstrating improvement in disease-related symptoms or long-term clinical outcomes in patients 16 months to 5 years of age<\/li><li><b>Mucopolysaccharidosis, MPS-II:<\/b> (16 months or older) 0.5 mg\/kg IV once a week, administered by infusion initially over 3 hours; may decrease infusion to 1 hour if no hypersensitivity reactions observed; infusion may last up to 8 hours if required to manage hypersensitivity reaction<\/li><\/ul>"},"3":{"id":"928570-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Mucopolysaccharidosis, MPS-II<br\/>"}}},"2":{"id":"928570-s-2","title":"Black Box Warning","mono":"<b>Intravenous (Solution)<\/b><br\/>Life-threatening anaphylactic reactions, presenting as respiratory distress, hypoxia, hypotension, urticaria, and\/or angioedema of throat or tongue have occurred in some patients during and up to 24 hours after idursulfase infusions, regardless of duration of the course of treatment. Closely observe patients during and after idursulfase administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.<br\/>"},"3":{"id":"928570-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928570-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928570-s-3-10","title":"Precautions","mono":"<ul><li>hypersensitivity reactions, including anaphylaxis (eg, respiratory distress, hypoxia, hypotension, urticaria, and\/or angioedema of throat or tongue), have been reported up to 24 hours after infusion; discontinue infusion immediately with onset of anaphylactic or acute reactions; monitoring recommended; premedication, slower infusion rate, and\/or early discontinuation recommended with subsequent infusions<\/li><li>anaphylactic events occurring repeatedly over a two- to four-month time period have been reported; anaphylactic reactions may occur up to several years after initiating treatment<\/li><li>cardiorespiratory failure, acute (eg, underlying respiratory illness, compromised cardiac and\/or respiratory function); increased risk of serious exacerbation of their cardiac or respiratory status during infusions, particularly in patients susceptible to fluid overload; monitoring recommended<\/li><li>pediatric Hunter syndrome patients age 7 years or younger with severe genetic mutations (complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations); increased risk of hypersensitivity, serious adverse reactions, and anti-idursulfase antibody development<\/li><li>respiratory complications, acute (eg, compromised respiratory function, acute febrile illness or respiratory illness); increased risk of life-threatening complications due to hypersensitivity reactions; consider delaying idursulfase infusion<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"928570-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928570-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"928570-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Flushing (7% to 16%), Pruritus (25%), Rash (19% to 32%), Urticaria (16%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (9%), Vomiting (5% to 14%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (13%)<\/li><li><b>Neurologic:<\/b>Headache (28%)<\/li><li><b>Respiratory:<\/b>Cough (9%)<\/li><li><b>Other:<\/b>Fatigue (13%), Fever (9% to 36%), Shivering (9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Cardiac dysrhythmia<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction (15% to 69%), Infectious disease<\/li><li><b>Musculoskeletal:<\/b>Arthralgia<\/li><li><b>Respiratory:<\/b>Cyanosis, Hypoxia, Pneumonia (18%), Pulmonary embolism, Respiratory failure<\/li><\/ul>"},"6":{"id":"928570-s-6","title":"Drug Name Info","sub":{"0":{"id":"928570-s-6-17","title":"US Trade Names","mono":"Elaprase<br\/>"},"2":{"id":"928570-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Enzyme Replacement<\/li><\/ul>"},"3":{"id":"928570-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928570-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928570-s-7","title":"Mechanism Of Action","mono":"Idursulfase, a purified form of human iduronate-2-sulfatase lysosomal enzyme, is used as an exogenous enzyme source to allow for catabolism of glycosaminoglycans (GAG) in patients with Hunter syndrome, where a deficiency of this enzyme results in GAG accumulation and subsequent organ dysfunction.<br\/>"},"8":{"id":"928570-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928570-s-8-24","title":"Distribution","mono":"<ul><li>Vd, aged 16 months to 7.5 years: 272 mL\/kg (negative anti-idursulfase antibodies [Ab]); 829 mL\/kg (positive Ab)<\/li><li>Vd, aged 7.7 to 27 years: 213 to 254 mL\/kg (steady-state)<\/li><\/ul>"},"3":{"id":"928570-s-8-26","title":"Excretion","mono":"<ul><li>Total body clearance: 16 months to 7.5 years of age, 2 mL\/min\/kg (negative anti-idursulfase antibodies [Ab]); 7.4 mL\/min\/kg (positive Ab)<\/li><li>Total body clearance: 7.7 to 27 years of age, 3 to 3.4 mL\/min\/kg<\/li><\/ul>"},"4":{"id":"928570-s-8-27","title":"Elimination Half Life","mono":"<ul><li>16 months to 7.5 years of age, 134 minutes with negative anti-idursulfase antibodies [Ab]); 84 minutes with positive Ab<\/li><li>7.7 to 27 years of age, 44 to 48 minutes<\/li><\/ul>"}}},"9":{"id":"928570-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>allow required number of vials to come to room temperature; prepare using aseptic technique<\/li><li>without shaking the vial, withdraw the requisite amount and dilute in 100 mL NS; mix the infusion bag gently; do not shake<\/li><li>use diluted solution immediately; if immediate use is not possible, store diluted solution refrigerated between 2 and 8 degrees C (36 and 46 degrees F) for up to 24 hours; do not store diluted solution at room temperature except during infusion<\/li><li>use an infusion set with a low-protein-binding, 0.2-micrometer, in-line filter<\/li><li>start infusion at a rate of 8 mL\/hr for the first 15 minutes; if tolerated, may increase rate in 8-mL\/hr increments every 15 minutes; do not exceed a rate of 100 mL\/hr; longer infusion times (up to 8 hours) may be used due to the possibility of infusion-related reactions<\/li><li>do not infuse other products in the same infusion tubing<\/li><\/ul>"},"10":{"id":"928570-s-10","title":"Monitoring","mono":"<ul><li>walking capacity (distance) in patients 5 years or older may indicate efficacy<\/li><li>reduction in spleen volume in patients 16 months or older may indicate efficacy<\/li><li>life-threatening anaphylactic reactions; during and up to 24 hours after infusion, regardless of previous treatment exposure, especially in patients with compromised respiratory function or acute febrile or respiratory disease, and in patients with complete gene deletion, large gene rearrangement, nonsense, frameshift or splice site mutations<\/li><li>serious exacerbation of cardiac or respiratory status; during infusion for prolonged observation times in those susceptible to fluid overload or who are fluid restricted due to underlying respiratory illness or compromised cardiac and\/or respiratory function<\/li><\/ul>"},"11":{"id":"928570-s-11","title":"How Supplied","mono":"<b>Elaprase<\/b><br\/>Intravenous Solution: 2 MG\/ML<br\/>"},"13":{"id":"928570-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause infusion-related reactions such as headache, fever, rash, pruritus, or hypertension.<\/li><li>Patients are encouraged to participate in the Hunter Outcome Survey. It has been established to better understand Hunter syndrome and to evaluate long-term effects of treatment with idursulfase. Information may be obtained by visiting www.eleprase.com or calling 1-866-888-0660.<\/li><\/ul>"}}}